ClinicalTrials.gg
CompletedNCT00789373Updated Dec 14, 2018Results posted

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer

A Phase 3 interventional study of Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 69 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-14.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
939
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 223
939 · median 64
Started
2008
with 13 others
Phase 3
44 of 227
4 open now
Registered
79th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2008, is one of 44 in phase 3, and was the 79th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will compare progression-free survival in patients with advanced non-squamous non-small cell lung cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be randomized 2:1 to receive either maintenance pemetrexed or placebo.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You must sign an document for clinical research.
  • You must have Stage IIIB or IV nonsquamous Non-Small Cell Lung Cancer.
  • You must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.
  • You are allowed to have had prior radiation therapy as long as it was not to more than 25% of the bone marrow and did not include the whole pelvis. Thoracic radiation must be completed more than 30 days before the study. You must be recovered from the toxic effects (except hair loss).
  • You must have at least 1 measurable tumor lesion according to the (RECIST) guidelines or disease that can be evaluated by computed tomography (CT) Scan.
  • Your test results assessing the function of your blood forming tissue, kidneys, and liver must be satisfactory.
  • You must be 18 years of age or older.
  • Women must be sterile, or on and men must be on contraception or sterile (e.g. post-vasectomy).

Exclusion criteria

Exclusion Criteria for the Induction Phase:

  • You cannot have squamous cell and/or mixed small cell, non-small cell lung cancer
  • You cannot have received other drugs within the last 30 days of entering the trial.
  • You cannot have previously completed or withdrawn from this study or any other study investigating pemetrexed.
  • You cannot have other serious on-going illnesses including active infections.
  • You cannot have a serious cardiac condition, such as a heart attack, angina, or heart disease within 6 months of entering the trial.
  • You cannot have had another form of cancer other than superficial basal cell and superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the last 5 years. Patients with a history of low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed less than 5 years ago.
  • You cannot have known central nervous system (CNS) , other than treated, stable .
  • You cannot be receiving nor have received any prior systemic anticancer therapy for lung cancer (including chemotherapy given after surgery in early-stage treatment).
  • You cannot have third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).
  • You cannot have received a recent (within 30 days) or are receiving a yellow fever vaccination.
  • You are unable to stop taking more than 1.3 grams of aspirin on a daily basis or other non-steroidal anti-inflammatory drugs (NSAIDs).
  • You are unable or unwilling to take folic acid, injections of vitamin B12, or .
  • You cannot be pregnant or breastfeeding.

Inclusion criteria at Randomization for the Maintenance Phase:

  • You must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.
  • You must have documented radiographic evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD) according to the (RECIST) guidelines. Tumor assessment must occur between Cycle 4 (Day 1) of induction therapy and the date of randomization. This response does not have to be confirmed in order for the patient to be randomized to the maintenance phase.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
939 participants (actual)

Study arms

  • Experimental
    pemetrexed + cisplatin followed by pemetrexed

    pemetrexed plus cisplatin followed by pemetrexed plus best supportive care

    Drug: Pemetrexed · Drug: Cisplatin · Other: Best Supportive Care

  • Placebo comparator
    pemetrexed + cisplatin followed by placebo

    pemetrexed plus cisplatin followed by placebo plus best supportive care

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Placebo · Other: Best Supportive Care

Interventions

  • Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles

    Also known as: Alimta, LY231514

  • Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles

  • DrugPlacebo

    Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation

  • Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.

    Also known as: Alimta, LY231514

  • OtherBest Supportive Care

    Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).

06

What researchers measure

Primary outcomes

  1. Investigator-assessed Objective Progression-free Survival (PFS)

    Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.

    Time frame: Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)

Secondary outcomes

  1. Independently-assessed Objective Progression-free Survival (PFS)

    To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.

    Time frame: Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)

  2. Overall Survival (OS)

    OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.

    Time frame: Date of randomization to the date of death from any cause up to 39.5 months

  3. Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score

    The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).

    Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)

  4. Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)

    Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)

  5. Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)

    Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)

  6. Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase

    A summary of non-serious AEs is located in the Reported Adverse Event Module.

    Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)

  7. Percentage of Participants With Serious Adverse Events During Maintenance Phase

    A summary of serious adverse events is located in the Reported Adverse Event Module.

    Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)

  8. Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off

    Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.

    Time frame: Baseline to date of measured progressive disease (up to 19.3 months)

  9. Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm\*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm\*100.

    Time frame: Date of randomization to date of measured PD (up to 19.3 months)

07

Results

Posted Jul 18, 2011

Participant flow

Induction
Participant flow — Induction
MilestoneInduction Pemetrexed + CisplatinPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Started93900
Completed54000
Not completed39900
Withdrew: Adverse event6400
Withdrew: Death due to study disease2400
Withdrew: Death due to adverse event1900
Withdrew: Death due to toxicity1100
Withdrew: Death due to procedure100
Withdrew: Investigator decision700
Withdrew: Protocol entry criteria not met900
Withdrew: Lost to follow-up600
Withdrew: Protocol violation100
Withdrew: Progressive disease22000
Withdrew: Withdrawal by subject3700
Maintenance
Participant flow — Maintenance
MilestoneInduction Pemetrexed + CisplatinPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Started0359180
Completed000
Not completed0359180
Withdrew: Adverse event06512
Withdrew: Death due to study disease031
Withdrew: Death due to adverse event041
Withdrew: Death due to toxicity012
Withdrew: Investigator decision042
Withdrew: Protocol entry criteria not met020
Withdrew: Lost to follow-up020
Withdrew: Progressive disease0253152
Withdrew: Withdrawal by subject0218
Withdrew: Sponsor decision002
Withdrew: Participants on-going at data cut-off040

Outcome measures

PrimaryInvestigator-assessed Objective Progression-free Survival (PFS)

Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.

Time frame:
Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)
Reported as:
Median · months
Investigator-assessed Objective Progression-free Survival (PFS)
monthsPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Investigator-assessed Objective Progression-free Survival (PFS)4.11 (3.15 to 4.57)2.83 (2.60 to 3.12)
Statistical analysis
  • Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed vs Pemetrexed + Cisplatin Followed by Placebo · Log Rank · p = 0.00006 · Hazard ratio (hr): 0.62 · 95% CI 0.49 to 0.79
SecondaryIndependently-assessed Objective Progression-free Survival (PFS)

To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.

Time frame:
Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)
Reported as:
Median · months
Independently-assessed Objective Progression-free Survival (PFS)
monthsPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Independently-assessed Objective Progression-free Survival (PFS)3.94 (2.96 to 4.24)2.60 (2.23 to 2.92)
Statistical analysis
  • Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed vs Pemetrexed + Cisplatin Followed by Placebo · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.64 · 95% CI 0.51 to 0.81
SecondaryOverall Survival (OS)

OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.

Time frame:
Date of randomization to the date of death from any cause up to 39.5 months
Reported as:
Median · months
Overall Survival (OS)
monthsPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Overall Survival (OS)13.86 (12.75 to 16.03)11.01 (9.95 to 12.52)
Statistical analysis
  • Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed vs Pemetrexed + Cisplatin Followed by Placebo · Log Rank · p = 0.0195 (The predefined alpha for the final analysis of OS is 0.0498 for the unadjusted log-rank test.) · Hazard ratio (hr): 0.78 · 95% CI 0.64 to 0.96Unadjusted HR from Cox model with treatment as the only cofactor.
SecondaryChange From Baseline in the EuroQol Instrument (EQ-5D) Index Score

The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).

Time frame:
Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)
Reported as:
Mean · units on a scale
Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score
units on a scalePemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Baseline0.77 ± 0.210.79 ± 0.18
Cycle 1 Day 10.01 ± 0.15-0.01 ± 0.17
Cycle 2 Day 10.0 ± 0.190.01 ± 0.17
Cycle 3 Day 10.0 ± 0.150.03 ± 0.17
Cycle 4 Day 1-0.01 ± 0.150.02 ± 0.18
Cycle 5 Day 10.01 ± 0.160.01 ± 0.22
Cycle 6 Day 1-0.02 ± 0.180.04 ± 0.14
Cycle 7 Day 10.01 ± 0.200.01 ± 0.13
Cycle 8 Day 10.01 ± 0.180.05 ± 0.15
Cycle 9 Day 1-0.03 ± 0.200.06 ± 0.18
Cycle 10 Day 10.0 ± 0.160.08 ± 0.15
Cycle 11 Day 1-0.02 ± 0.190.04 ± 0.17
Cycle 12 Day 1-0.06 ± 0.270.06 ± 0.16
Cycle 13 Day 1-0.01 ± 0.270.0 ± 0.0
Cycle 14 Day 10.03 ± 0.260.03 ± 0.05
Cycle 15 Day 1-0.07 ± 0.340.01 ± 0.02
Cycle 16 Day 1-0.01 ± 0.360.0 ± 0.0
Cycle 17 Day 10.32 ± 0.43—
Cycle 18 Day 10.45 ± 0.52—
30 Day Post-Study Visit-0.13 ± 0.27-0.09 ± 0.26
SecondaryChange From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)

Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)
units on a scalePemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Baseline71.1 ± 16.671.0 ± 15.8
Cycle 1 Day 11.65 ± 9.861.42 ± 10.2
Cycle 2 Day 11.24 ± 11.23.15 ± 13.0
Cycle 3 Day 11.82 ± 10.94.90 ± 16.9
Cycle 4 Day 10.69 ± 13.16.15 ± 16.4
Cycle 5 Day 11.55 ± 12.45.99 ± 13.1
Cycle 6 Day 13.01 ± 12.55.76 ± 12.9
Cycle 7 Day 12.7 ± 14.53.98 ± 10.9
Cycle 8 Day 14.12 ± 14.17.58 ± 14.8
Cycle 9 Day 14.19 ± 14.27.61 ± 16.7
Cycle 10 Day 15.14 ± 15.16.23 ± 18.7
Cycle 11 Day 12.58 ± 14.70.94 ± 15.4
Cycle 12 Day 12.11 ± 16.04.63 ± 13.1
Cycle 13 Day 16.29 ± 16.410.0 ± 3.27
Cycle 14 Day 13.64 ± 18.414.0 ± 4.55
Cycle 15 Day 18.40 ± 12.912.0 ± 3.46
Cycle 16 Day 15.83 ± 9.9915.0 ± 0.0
Cycle 17 Day 115.7 ± 21.1—
Cycle 18 Day 15.0 ± 14.1—
30 days post-study-4.77 ± 17.3-3.92 ± 16.7
SecondaryPercentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)
Time frame:
Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)
percentage of participantsPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Hospitalization due to Drug-related Adverse Event8.43.3
Transfusions Packed Red Blood Cells12.34.4
Transfusions Whole Blood1.40.6
Transfusions Platelets1.40.6
Transfusions Fresh Frozen Plasma00.6
SecondaryPercentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase

A summary of non-serious AEs is located in the Reported Adverse Event Module.

Time frame:
Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase
percentage of participantsPemetrexed Plus Cisplatin Followed by Maintenance PemetrexedPemetrexed Plus Cisplatin Followed by Placebo
Non-Serious AEs at 2% Threshold: up to 19.3 Month59.950.6
Non-Serious AEs at 5% Threshold: up to 49.7 Months75.562.2
SecondaryPercentage of Participants With Serious Adverse Events During Maintenance Phase

A summary of serious adverse events is located in the Reported Adverse Event Module.

Time frame:
Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events During Maintenance Phase
percentage of participantsPemetrexed Plus Cisplatin Followed by Maintenance PemetrexedPemetrexed Plus Cisplatin Followed by Placebo
Serious Adverse Events: up to 19.3 Months18.912.2
Serious Adverse Events: up to 49.7 Months26.220.0
SecondaryPercentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off

Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.

Time frame:
Baseline to date of measured progressive disease (up to 19.3 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off
percentage of participantsPemetrexed Plus Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off46.242.2
SecondaryPercentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm\*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm\*100.

Time frame:
Date of randomization to date of measured PD (up to 19.3 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off
percentage of participantsPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
Response Rate46.2 (41.0 to 51.6)42.2 (34.9 to 49.8)
Disease Control Rate98.1 (96.0 to 99.2)94.4 (90.0 to 97.3)

Adverse events

Collected over From start of study up to approximately 108 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Pemetrexed + Cisplatin—257/939 (27.4%)759/939 (80.8%)
Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed—94/359 (26.2%)287/359 (79.9%)
Pemetrexed + Cisplatin Followed by Placebo—36/180 (20%)117/180 (65%)
Most frequent serious events
Showing 10 of 228
Most frequent serious events
EventInduction Pemetrexed + CisplatinPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
VomitingGastrointestinal disorders29/9393/3591/180
AnaemiaBlood and lymphatic system disorders13/93911/3591/180
Pulmonary embolismRespiratory, thoracic and mediastinal disorders28/9393/3593/180
NauseaGastrointestinal disorders24/9392/3591/180
Back painMusculoskeletal and connective tissue disorders4/9391/3594/180
PneumoniaInfections and infestations17/9395/3593/180
Febrile neutropeniaBlood and lymphatic system disorders12/9396/3590/180
NeutropeniaBlood and lymphatic system disorders8/9396/3590/180
DyspnoeaRespiratory, thoracic and mediastinal disorders15/9396/3593/180
ThrombocytopeniaBlood and lymphatic system disorders7/9395/3590/180
Most frequent other events
Showing 10 of 19
Most frequent other events
EventInduction Pemetrexed + CisplatinPemetrexed + Cisplatin Followed by Maintenance PemetrexedPemetrexed + Cisplatin Followed by Placebo
NauseaGastrointestinal disorders362/93969/3598/180
VomitingGastrointestinal disorders210/93942/3599/180
AnaemiaBlood and lymphatic system disorders152/93976/3595/180
FatigueGeneral disorders181/93955/35916/180
NeutropeniaBlood and lymphatic system disorders158/93938/3593/180
AstheniaGeneral disorders141/93951/3598/180
ConstipationGastrointestinal disorders131/93923/35914/180
Decreased appetiteMetabolism and nutrition disorders119/93932/3596/180
Oedema peripheralGeneral disorders42/93945/3595/180
DiarrhoeaGastrointestinal disorders114/93928/3597/180

Baseline characteristics

Age, Continuous
Age, Continuous(years)Induction Pemetrexed + Cisplatin
Median61.3 (24.4 to 83.0)
Sex: Female, Male
Sex: Female, Male(Participants)Induction Pemetrexed + Cisplatin
Female362
Male577
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Induction Pemetrexed + Cisplatin
Asian59
African7
Multiple2
Caucasian871
Region of Enrollment
Region of Enrollment(participants)Induction Pemetrexed + Cisplatin
Portugal38
Greece34
Finland18
Spain65
Turkey33
United Kingdom71
Italy175
India54
France106
Poland34
Belgium53
Romania55
Australia26
Netherlands48
Germany126
Canada3
Smoking Status
Smoking Status(participants)Induction Pemetrexed + Cisplatin
Ever Smoker757
Never Smoker175
Unknown7
08

Study locations

69 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adelaide, South Australia 5000, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankston, Victoria 3199, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wendouree, Victoria 3355, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aalst, 9300, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1200, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genk, 3600, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gilly, 6060, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liege, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sint Niklaas, 9100, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Espoo, 02740, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Helsinki, 00290, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampere, 33520, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Turku, 20520, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Avignon, 84082, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dijon, 21034, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Le Mans Cedex 1, 72037, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, F-34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44202, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75015, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vandoeuvre Les Nancy, 54511, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vandoeuvre-Les-Nancy, 54511, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt, 60596, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gerlingen, 70839, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Großhansdorf, D-22927, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, D-20251, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heidelberg, 69126, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulm, 89075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chania, 73300, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neo Faliro, 18547, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560 078, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bhopal, 462001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madurai, 625020, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 400 012, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patna, 800 014, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Avellino, 83100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aviano, 33081, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genova, 16132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lido Di Camaiore, 55043, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monza, 20052, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pisa, 56100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reggio Emilia, 42100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00149, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Udine, 33100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ede, 6716 RP, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Groningen, 9728 NT, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Harderwijk, 3844 DG, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heerlen, 6419 PC, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 60-569, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-781, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coimbra, 3040-853, Portugal
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lisbon, 1099-035, Portugal
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vila Franca De Xira, 4434-502, Portugal
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 022328, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cluj-Napoca, 3400, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oradea, 3700, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manresa, 308243, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sabadell, 08208, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46017, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zaragoza, 50009, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bornova, 35100, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sihhiye, 06100, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zeytinburnu, 034760, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aberdeen, Scotland AB25 2ZN, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guildford, Surrey GU2 7XX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Birmingham, West Midlands B15 2TH, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newcastle, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Visseren-Grul CM, San Antonio B, John WJ, Zimmermann AH, Chouaki N, Paz-Ares L. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 2018 May;34(5):865-871. doi: 10.1080/03007995.2018.1439462. Epub 2018 Mar 27. PubMed 29424248 ↗
  • Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P, Corral J, San Antonio B, Chouaki N, John W, Zimmermann A, Visseren-Grul C, Gridelli C. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov;15(6):418-25. doi: 10.1016/j.cllc.2014.06.007. Epub 2014 Jun 21. PubMed 25104617 ↗
  • Reck M, Paz-Ares LG, de Marinis F, Molinier O, Sahoo TP, Laack E, John W, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2014 Feb;9(2):205-13. doi: 10.1097/JTO.0000000000000076. PubMed 24419418 ↗
  • Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8. PubMed 23835707 ↗
  • Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Clin Ther. 2013 Jan;35(1):54-65. doi: 10.1016/j.clinthera.2012.12.013. PubMed 23328269 ↗
  • Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012 Nov;7(11):1713-21. doi: 10.1097/JTO.0b013e318267cf84. PubMed 23059776 ↗
  • Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16. PubMed 22341744 ↗
  • Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer. 2010 Mar 8;10:85. doi: 10.1186/1471-2407-10-85. PubMed 20211022 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Jun 2010 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2008
First posted
Nov 11, 2008
Start
Nov 2008
Primary completionActual
Jun 2010
CompletionActual
Nov 2017
Results first posted
Jul 18, 2011
Last update
Dec 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00789373
Responsible party
Sponsor
First posted
Nov 11, 2008
Start date
Nov 2008
Primary completion
Jun 2010
Completion
Nov 2017
Results posted
Jul 18, 2011
Last update
Dec 14, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion